VerifyMe (VRME) 10-Q 19 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 14, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	LLTI
Entity Registrant Name	VerifyMe, Inc.
Entity Central Index Key	1,104,038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,502,106

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 1,010,554	$ 63,956
Accounts receivable	62,125
Inventory	74,576	97,360
Prepaid expenses	178,684	181,086
TOTAL CURRENT ASSETS	1,325,939	342,402
PROPERTY AND EQUIPMENT
Capital equipment, net of accumulated depreciation of $195,832 and $161,205 as of June 30, 2015 and December 31, 2014	40,194	74,821
OTHER ASSETS
Deposits	37,197	37,197
Patents and Trademark, net of accumulated amortization of $126,818 and $118,502 as of June 30, 2015 and December 31, 2014	99,370	107,586
TOTAL OTHER ASSETS	136,567	144,783
TOTAL ASSETS	1,502,700	562,006
CURRENT LIABILITIES
Accounts payable and accrued expenses	736,022	5,217,770
Accrued interest - related parties		43,215
Deferred revenue	4,167	16,667
Senior secured convertible notes payable - related parties		114,000
Notes payable		812,553
TOTAL CURRENT LIABILITIES	740,189	6,204,205
LONG-TERM LIABILITIES
Warrant liability	3,182,504	6,370,709
Accrued interest - related parties		112,885
TOTAL LONG-TERM LIABILITIES	3,182,504	6,483,594
TOTAL LIABILITIES	$ 3,922,693	$ 12,687,799
CONTINGENCIES
STOCKHOLDERS' DEFICIT
Common stock, $ .001 par value; 675,000,000 shares authorized; 5,852,646 and 3,969,106 shares issued, and 5,502,106 3,618,566 shares outstanding at June 30, 2015 and December 31, 2014	$ 5,502	$ 3,618
Additional paid in capital	37,043,871	25,047,050
Treasury stock, at cost (350,540 shares at June 30, 2015 and December 31, 2014)	(113,389)	(113,389)
Deferred compensation	(440,052)
Accumulated deficit	(38,916,367)	(37,696,405)
STOCKHOLDERS' DEFICIT	(2,419,993)	(12,125,793)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,502,700	562,006
Series A Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
Series A Convertible Preferred Stock, $ .001 par value; 37,564,767 shares authorized; 441,938 shares issued and outstanding as of June 30, 2015 and 75,000,000 shares authorized; 248,366 issued and outstanding as of December 31, 2014	$ 442	$ 633,333

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accumulated depreciation on capital equipment	$ 195,832	$ 161,205
Accumulated amortization, patent and trademarks	$ 126,818	$ 118,502
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	675,000,000	675,000,000
Common stock, shares issued	5,852,646	3,969,106
Common stock, shares outstanding	5,502,106	3,618,566
Treasury stock, shares	350,540	350,540
Series A Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	37,564,767	75,000,000
Preferred stock, shares issued	441,938	248,366
Preferred stock, shares outstanding	441,938	248,366
Series B Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	85	0
Preferred stock, shares issued	1	0
Preferred stock, shares outstanding	1	0

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
NET REVENUES
Sales		$ 62,125	$ 65,148	$ 62,125	$ 65,148
Royalties		6,250		12,500
TOTAL NET REVENUE		68,375	65,148	74,625	65,148
COST OF SALES		36,079	54,440	36,079	54,440
GROSS PROFIT		32,296	10,708	38,546	10,708
OPERATING EXPENSES
General and administrative		80,129	276,108	164,030	520,604
Legal and accounting		217,322	177,872	228,435	291,198
Payroll expenses	[1]	119,235	278,553	290,139	1,232,881
Research and development	[2]	2,016,000	83,887	2,136,386	948,616
Sales and marketing		319	73,895	23,127	125,817
Total operating expenses		2,433,005	890,315	2,842,117	3,119,116
LOSS BEFORE OTHER INCOME		(2,400,709)	(879,607)	(2,803,571)	(3,108,408)
OTHER INCOME (EXPENSE)
Interest expense		(24,904)	(13,121)	(55,154)	(24,028)
Gain (Loss) on extinguishment of debt		351,918	(82,000)	351,918	(82,000)
Change in fair value of warrant liability		1,117,369	3,726,572	1,286,845	2,836,572
Change in fair value of embedded derivative liability			900,000		600,000
TOTAL OTHER INCOME (EXPENSE)		1,444,383	4,531,451	1,583,609	3,330,544
NET INCOME (LOSS)		$ (956,326)	$ 3,651,844	$ (1,219,962)	$ 222,136
EARNINGS PER SHARE
BASIC		$ (0.24)	$ 1.03	$ (0.32)	$ 0.06
DILUTED		$ (0.24)	$ 0.96	$ (0.32)	$ 0.06
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC		3,934,451	3,553,408	3,777,685	3,527,720
DILUTED		3,934,451	3,807,068	3,777,685	3,781,380
[1]	includes share based compensation of $88,928 and $34,094 for the three and six months ended June 30, 2015 and $61,312 and $802,267 for the three and six months ended June 30, 2014
[2]	includes shares based compensation of $2,000,000 for the three and six months ended June 30, 2015 and $0 and $400,000 for the three and six months ended June 30, 2014, related to licensing agreements.

Statements of Operations (Unau5

Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Payroll expenses
Share based compensation	$ 88,928	$ 61,312	$ 34,094	$ 802,267
Research and Development Expense
Share based compensation	$ 2,000,000	$ 0	$ 2,000,000	$ 400,000

Statements of Changes in Stockh

Statements of Changes in Stockholders' Deficit - 6 months ended Jun. 30, 2015 - USD ($)	Total	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Treasury Stock	Deferred Compensation	Accumulated Deficit
Balance at Dec. 31, 2014	$ (12,125,793)	$ 633,333		$ 3,618	$ 25,047,050	$ (113,389)		$ (37,696,405)
Balance (in shares) at Dec. 31, 2014		248,366		3,618,566
Conversion of Series A Convertible Preferred Stock into common stock		$ (633,333)		$ 249	633,084
Conversion of Series A Convertible Preferred Stock into common stock (in shares)		(248,366)		248,366
Sale of stock	1,278,501	$ 390			1,278,111
Sale of stock (in shares)		389,668
Conversion of stockholder deferred compensation into Series A Convertible Preferred Stock	35,000	$ 10			34,990
Conversion of stockholder deferred compensation into Series A Convertible Preferred Stock (in shares)		10,667
Conversion of notes payable and accrued interest into Series A Convertible Preferred Stock	136,813	$ 42			136,771
Conversion of notes payable and accrued interest into Series A Convertible Preferred Stock (in shares)		41,603
Conversion of accrued expenses into Series B Convertible Preferred Stock	6,500,000				6,500,000
Conversion of accrued expenses into Series B Convertible Preferred Stock (in shares)			1
Conversion of warrants	1,867,417				1,867,417
Sale of stock	50,000			$ 305	49,695
Sale of stock (in shares)				304,785
Conversion of warrants	40,000			$ 47	39,953
Conversion of warrants (in shares)				47,059
Conversion of stockholder notes payable and accrued interest into common stock	802,453			$ 756	801,697
Conversion of stockholder notes payable and accrued interest into common stock (in shares)				755,977
Cashless exercise of options into common stock				$ 2	(2)
Cashless exercise of options into common stock (in shares)				2,353
Issuance of common stock for services				$ 525	445,725		$ (446,250)
Issuance of common stock for services (in shares)				525,000
Forgiveness of stockholder compensation	175,287				175,287
Amortization of deferred compensation	6,198						6,198
Fair value of employee stock options	34,093				34,093
Net loss	(1,219,962)							(1,219,962)
Balance at Jun. 30, 2015	$ (2,419,993)	$ 442		$ 5,502	$ 37,043,871	$ (113,389)	$ (440,052)	$ (38,916,367)
Balance (in shares) at Jun. 30, 2015		441,938	1	5,502,106

Statements of Changes in Stock7

Statements of Changes in Stockholders' Deficit (Parenthetical)	6 Months Ended
	Jun. 30, 2015USD ($)
Gain on conversion of stockholder notes payable and accrued interest	$ 351,918
Common Stock
Gain on conversion of stockholder notes payable and accrued interest	351,918
Additional Paid-In Capital
Gain on conversion of stockholder notes payable and accrued interest	$ 351,918

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ (1,219,962)	$ 222,136
Adjustments to reconcile net loss to net cash used in operating activities
Gain on conversion of debt	(351,918)
Fair value of options issued in exchange for services	34,093	802,267
Accretion of discount on notes payable	10,447
Change in fair value of warrant liability	(1,286,845)	(2,836,572)
Change in fair value of embedded derivative liability		(600,000)
Fair value of stock in excess of converted notes payable and accrued interest		82,000
Amortization and depreciation	42,943	41,180
Stock and warrants issued in exchange for technology		844,000
Amortization of deferred compensation	6,198
(Increase) decrease in assets
Accounts receivable	(62,125)	(55,148)
Inventory	22,784	(50,013)
Prepaid expenses	2,402	5,263
Increase (decrease) in liabilities
Accounts payable and accrued expenses	2,273,138	116,684
Deferred revenue	(12,500)
Net cash used in operating activities	(541,345)	(1,428,203)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of patents	(100)
Net cash used in investing activities	(100)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable	159,542	250,000
Proceeds from sale of Series A Convertible Preferred Stock	1,278,501
Proceeds from sale of common stock	50,000
Net cash provided by financing activities	1,488,043	250,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	946,598	(1,178,203)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	63,956	1,285,973
CASH AND CASH EQUIVALENTS - END OF PERIOD	1,010,554	107,770
Cash paid during the year for:
Interest	0	0
Income taxes	0	0
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Fair value of stock issued for conversion of notes payable and accrued interest		424,588
Fair value of warrants issued as debt discount		$ 34,222
Cashless exercise of warrants	2
Series A Convertible Preferred Stock converted to common stock	633,333
Issuance of Series A Convertible Preferred Stock for deferred compensation	35,000
Issuance of Series A Convertible Preferred Stock for stockholder notes payable and accrued interest	136,813
Issuance of Series B Convertible Preferred Stock for accrued expenses	$ 6,500,000
Conversion of warrants associated with notes payable	1,867,417
Conversion of warrants to common stock	$ 40,000
Issuance of common stock for notes payable and accrued interest	801,697
Common stock issued for deferred compensation	446,250
Forgiveness of stockholder compensation	$ 175,285

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of the Business On July 14, 2015, LaserLock Technologies, Inc. changed its name to VerifyMe, Inc. (the “Company”), effective July 23, 2015. The Company was incorporated in the State of Nevada on November 10, 1999. The Company is based in New York, NY and its common stock is traded on the OTCQB under the ticker symbol “LLTI.D”. A high-tech solutions company in the field of authenticating people and products, the Company offers state-of-the-art solutions to combat identity fraud and counterfeiting utilizing multi-factor authentication and a suite of security pigments for governments, health care providers, the gaming industry, the financial services industry and high-end retailers. The Company invests in developing new proprietary color shifting inks that it believes will allow it to penetrate broader markets and result in increased revenues. The Company refines its technologies and their applications, and now has what it believes to be one of the most cost effective and efficient authentication technologies available. Its most recent technology takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in numerous potential new applications ranging from credit cards to drivers licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technologies can also be used to protect DVDs, apparel, pharmaceuticals, and virtually any other physical product. The Company’s digital solution is a multi-platform (iOS and Android) strong authentication solution that integrates biometrics and geo-location tagging. The solution completely eliminates passwords and the inherently weak security they provide. The solution also removes the user complexity associated with having to manage many complex passwords. The solution can be delivered either as a high availability cloud service, managed by the Company, or as a licensed software product for operation on the client’s premises. The solution integrates three independent authentication factors – something you have (for instance a smartphone), something you know (for instance a color gesture swipe) and something you are (for instance your facial geometry) - into a simple, fast, intuitive solution. The system can also accurately determine the precise location of the individual using a variety of mechanisms including GPS, cell tower triangulation, IP or WIFI address. Because the solution incorporates biometrics it completely eliminates the possibility that users might share their authentication credentials. The combination of biometrics and geolocation provides extremely strong transactional evidence, making it nearly impossible for an end-user to refute having been part of a transaction. The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to operationalize the Company’s current technology. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on form 10-K for the year ended December 31, 2014 as filed with the SEC. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. Reverse Stock Split and Amended and Restated Certificate of Incorporation On May 28, 2015, the stockholders voted to allow a reverse stock split between 1-for-40 and 1-for-100. On July 23, 2015, the Company completed a 1-for-85 reverse stock split of its outstanding common and preferred stock. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented. In addition, the reverse stock split resulted in an adjustment in the number of shares of common stock issuable upon conversion of the convertible preferred stock on a 1-for-85 ratio. In addition, the Company adopted an Amended and Restated Certificate of Incorporation, which provides that the Company’s authorized capital stock consists of 675 million shares of common stock, $0.001 par value per share, 37,564,767 million shares of Series A Convertible Preferred Stock, $0.001 par value per share and 85 shares of Series B Convertible Preferred Stock, $0.001 par value per share. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Comprehensive Income The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss). Fair Value of Financial Instruments The Company’s financial instruments consist of accounts receivable, accounts payable and accrued expenses, warrant liability and notes payable. The carrying value of accounts receivable, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures Level 1: Quoted market prices in active markets for identical assets or liabilities Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs that are not corroborated by market data The level in the fair value within which a fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. Cash and Cash Equivalents For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents. Concentration of Credit Risk Involving Cash and Cash Equivalents The Company’s cash and cash equivalents are held at one financial institution. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits. Inventory Inventory principally consists of penlights and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market. Property and Equipment Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operations. Patents and Trademark The Company has filed eleven patent applications relating to the Company technology. Currently we have 7 U.S. patents, 4 U.S. applications pending for allowance, and 5 foreign applications pending for allowance. The Company has also purchased a trademark. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be 17 to 20 years. Long-Lived Assets The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Deferred Financing Costs Costs incurred in securing long-term debt are deferred and amortized, as a charge to interest expense, over the term of the related debt. In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50 “Debt – Modification and Extinguishments.” Convertible Notes Payable Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature (BCF) as a debt discount, which is then accreted to interest expense over the life of the related debt using the straight-line method which approximates the effective interest method. Derivative Instruments The Company evaluates its convertible debt, preferred stock, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Topic 480 of the FASB ASC and Topic 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative, if required to be bifurcated, is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified as liabilities at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date. Revenue Recognition In accordance with Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition (Codified in FASB ASC 605), the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process. Income Taxes The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Tax years from 2011 through 2014 remain subject to examination by major tax jurisdictions. Stock-based Payments The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Non-employee equity based payments are recorded as an expense over the service period, as if the Company had paid cash for the services. At the end of each financial reporting period, prior to vesting or prior to the completion of the services, the fair value of the equity based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the equity based payments are fully vested or the service completed. Advertising Costs Advertising costs are expensed as incurred. Advertising costs were approximately $100 and $258 for the three and six months ended June 30, 2015 and $25,955 and $53,238 for the six months ended June 30, 2014 and are included in sales and marketing expenses. Research and Development Costs In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the three and six months ended June 30, 2015 were $2,016,000 and $2,136,386 and $83,887 and $948,616 for the three and six months ended June 30, 2014. Basic and Diluted Net Income per Share of Common Stock The Company follows FASB ASC 260 when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Basic net income per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted net income per common share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive, i.e., the exercise prices of the outstanding stock options were greater than the market price of the common stock. Anti-dilutive common stock equivalents, which were excluded from the calculation of number of dilutive common stock equivalents, amounted to 2,018,618 shares for the three and six months ended June 30, 2014. Segment Information The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with ASC 280, Segment Reporting, the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by ASC 280 can be found in the financial statements. Recently Adopted Accounting Pronouncements As of June 30, 2015 and for the three and six months then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted As of June 30, 2015, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company’s financial statements through 2017. Reclassifications Certain amounts in 2014 statement of operations have been reclassified in order for them to conform with the 2015 presentation.

Management Plans

Management Plans	6 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Management Plans	NOTE 2 – MANAGEMENT PLANS The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant losses and experienced negative cash flow from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company does not believe that its existing cash resources will be sufficient to sustain operations during the next twelve months. The Company currently needs to generate revenue in order to sustain its operations. In the event that the Company cannot generate sufficient revenue to sustain its operations, the Company will need to reduce expenses or obtain financing through the sale of debt and/or equity securities. The issuance of additional equity would result in dilution to existing stockholders. If the Company is unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms acceptable to the Company, the Company may be unable to execute upon the business plan or pay costs and expenses as they are incurred, which could have a material, adverse effect on the business, financial condition and results of operations. If sufficient revenues are not generated to sustain operations or additional funding cannot be obtained in the short term, the Company will need to reduce monthly expenditures to a level that will enable the Company to continue until such funds can be obtained. Successful completion of the Company’s development program, and the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investment or achieve an adequate sales level.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 3 – PROPERTY AND EQUIPMENT Equipment consists of the following: June 30, December 31, 2015 2014 Furniture and Fixtures $ 219,871 $ 219,871 Equipment 16,155 16,155 236,026 236,026 Less: Accumulated depreciation 195,832 161,205 $ 40,194 $ 74,821 Depreciation of property and equipment was $17,313 and $34,626 for the three and six months ended June 30, 2015 and 2014.

Patents and Trademark

Patents and Trademark	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and Trademark	NOTE 4 – PATENTS AND TRADEMARK The Company has filed eleven patent applications relating to the Company technology. Currently the Company has 7 U.S. patents, 4 U.S. applications pending for allowance, and 5 foreign applications pending for allowance. Accordingly, costs associated with the registration of these patents and legal defense have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents (17 to 20 years). During three and six months ended June 30, 2015, the Company capitalized $100 and during the three and six months ended June 30, 2014, the Company capitalized $0 of patent costs. Amortization expense for patents was $4,203 and $8,406 for the three and six months ended June 30, 2015 and $3,277 and $6,554 for the three and six months ended June 30, 2014. On March 30, 2015, the Company was advised by the United States Patent and Trademark Office (“USPTO”) that its petition for an unintentional delayed payment for an unpaid maintenance fee to reinstate its patent was granted by the USPTO. The patent, for a counterfeiting ink detection system, was granted on November 2, 2004.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 5 – INCOME TAXES Income tax expense was $0 for the three and six months ended June 30, 2015 and 2014. As of January 1, 2015, the Company had no unrecognized tax benefits, and accordingly, the Company did not recognize interest or penalties during 2014 related to unrecognized tax benefits. There has been no change in unrecognized tax benefits during the three and six months ended June 30, 2015, and there was no accrual for uncertain tax positions as of June 30, 2015. Tax years from 2011 through 2014 remain subject to examination by major tax jurisdictions. There is no income tax benefit for the losses for the three and six months ended June 30, 2015 since management has determined that the realization of the net tax deferred asset is not assured and has created a valuation allowance for the entire amount of such benefits. The Company had income for the three and six months ended June 30, 2014; however, due to tax adjustments, the Company had a loss for income tax purposes.

Recapitalization Transaction

Recapitalization Transaction	6 Months Ended
	Jun. 30, 2015
Brokers and Dealers [Abstract]
Recapitalization Transaction	NOTE 6 – RECAPITALIZATION TRANSACTION On June 12, 2015, the Company Pursuant to the Master Agreement, the Company entered into several other material definitive agreements (collectively, the “ Transaction Documents Note Conversion Agreement. Warrant Conversion Agreement. Preferred Stock Conversion Agreement. Patent and Technology License Termination Agreement. Termination of Registration Rights. Termination of Technology and Services Agreement. Termination of Investment Agreement. Patent Purchase Agreement. Termination of Zaah Technology and Services Agreement. Series A Preferred Stock Subscription Agreement. Common Stock Subscription Agreement.

Senior Secured Convertible Note

Senior Secured Convertible Notes Payable -Related Parties	6 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Senior Secured Convertible Notes Payable -Related Parties	NOTE 7 – SENIOR SECURED CONVERTIBLE NOTES PAYABLE –RELATED PARTIES During the second quarter of 2014, $216,249 of principal of the Company’s outstanding senior convertible notes held by a significant stockholder of the Company, plus accrued interest of $208,339, were converted into 8,448,519 shares of common stock. The excess of the fair value of the Company’s common stock over the value of the notes payable and accrued interest, $82,000, was recorded as loss on extinguishment of debt in accordance with FASB ASC 470-50. On June 12, 2015, as part of the Recapitalization Transaction (see Note 6), the Company restructured the Senior Secured Convertible Notes Payable – Related Parties. As a result the principal balance of $114,000 and accrued interest of $118,775 was converted into 154,184 shares of the Company’s common stock (13,105,662 shares pre reverse split at $0.018). This resulted in a gain of $103,456. Of this amount $17,967 was related to a stockholder and recorded as additional paid in capital, with the remaining $85,489, being recorded as a gain on extinguishment of debt.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	NOTE 8 – NOTES PAYABLE Notes payable consists of the following at June 30, 2015 and December 31, 2014: June 30, December 31, 2015 2104 Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015 — $ 114,000 Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due) — 50,000 Notes payable; interest at 8% per annum, principal and accrued interest due at December 1, 2014 (past due) — 650,000 Notes payable; interest at 5% and 8% per annum, principal and accrued interest due at April 2015 — 123,000 Notes payable; interest at 5% per annum, principal and accrued interest due at June 10, 2015 — — Notes payable; interest at 8% per annum, principal and accrued interest due at June 25, 2015 — — Less: Debt discount — (10,447 ) — 926,553 Less: Current portion — 926,553 $ — $ — The warrant liabilities in this section were valued using the Black-Scholes option pricing model, with the following assumptions: no dividend yield, expected volatility of 173.7% to 180.7%, risk free interest rate of 1.75% and expected lives of 4 to 5 years. As a result of the Recapitalization Transaction, the principal balance of $50,000 of the Series A notes payable and accrued interest of $22,500 was converted into 47,370 shares of the Company’s common stock (4,026,484 shares pre reverse split at $0.018). This resulted in a gain of $30,959, which was recorded as a gain on the extinguishment of debt. On June 10, 2014, the Company issued a note payable for $250,000, which included fully vested warrants to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, expiring in five years. The warrants were valued at $39,650 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 248.2%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $34,222 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition As a result of the Recapitalization Transaction, the principal balance of $250,000 and accrued interest of $20,263 was converted into 176,471 shares of the Company’s common stock (15,000,000 shares pre reverse split at $0.018). This resulted in a gain of $120,117, and because this individual is a stockholder was recorded as additional paid in capital. On August 5, 2014, the Company issued notes payable for $100,000, which included fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $29,725 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $22,914 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition As a result of the Recapitalization Transaction, the principal balance of $100,000 and accrued interest of $6,828 was converted into 69,797 shares of the Company’s common stock (5,932,724 shares pre reverse split at $0.018). This resulted in a gain of $47,479, which was recorded as a gain on the extinguishment of debt. On August 12, 2014, the Company issued a notes payable for $50,000, which included fully vested warrants to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $26,817 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $17,455 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition As a result of the Recapitalization Transaction, the principal balance of $50,000 and accrued interest of $3,370 was converted into 34,843 shares of the Company’s common stock (2,961,644 shares pre reverse split at $0.018). This resulted in a gain of $23,720, which was recorded as a gain on the extinguishment of debt. On August 14, 2014, the Company issued a note payable for $100,000, which included fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $47,676 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $32,274 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition As a result of the Recapitalization Transaction, the principal balance of $100,000 and accrued interest of $6,697 was converted into 69,657 shares of the Company’s common stock (5,920,852 shares pre reverse split at $0.018). This resulted in a gain of $47,421, which was recorded as a gain on the extinguishment of debt. On September 8, 2014, the Company issued notes payable for $150,000, which included fully vested warrants to purchase 900,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $62,544 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $44,140 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition As a result of the Recapitalization Transaction, the principal balance of $150,000 and accrued interest of $9,223 was converted into 103,991 shares of the Company’s common stock (8,839,269 shares pre reverse split at $0.018). This resulted in a gain of $70,766, which was recorded as a gain on the extinguishment of debt. On December 5, 2014, the Company issued a note payable for $23,000 to a stockholder, which bears interest at 5.0% and was due on April 5, 2015. As a result of the Recapitalization Transaction (see Note 6), the principal balance of $23,000 and accrued interest of $609 was converted into 15,418 shares of the Company’s common stock (1,310,510 shares pre reverse split at $0.018). This resulted in a gain of $10,493 and because this entity is a stockholder was recorded as additional paid in capital. On December 31, 2014, the Company issued a note payable for $100,000, which include fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share expiring in five years. The warrants were valued at $11,812 using the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 229.0%, risk free interest rate of 1.68% and expected life of 5 years. The relative fair value of the warrants was $10,563 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition As a result of the Recapitalization Transaction, the principal balance of $100,000 and accrued interest of $3,689 was converted into 67,637 shares of the Company’s common stock (5,749,163 shares pre reverse split at $0.018). This resulted in a gain of $46,084, which was recorded as a gain on the extinguishment of debt. On February 10, 2015, the Company issued a note payable for $25,000, bearing interest at 5.0% to an accredited investor and director of the Company. As a result of the recapitalization transaction (see Note 6), the principal balance of $25,000 and accrued interest of $417 was converted into 16,608 shares of the Company’s common stock (1,411,720 shares pre reverse split at $0.018). This resulted in a gain of $11,296 and because this entity is a stockholder was recorded as additional paid in capital. The conversion of the notes above on June 12, 2015 will be treated as an extinguishment of debt. In accordance with FASB ASC 470-50, On March 27, 2015, the Company issued a note payable for $111,102, bearing interest at 8.0% to an accredited investor. On April 30, 2015, the Company issued a note payable for $4,887, bearing interest at 8.0% to an accredited investor. On May 15, 2015, the Company issued a note payable for $4,480, bearing interest at 8.0% to an accredited investor. On May 21, 2015, the Company issued a note payable for $14,074, bearing interest at 8.0% to an accredited investor. As a result of the Recapitalization Transaction (see Note 6), the principal balance of the above four notes of $134,542 and accrued interest of $2,271 was converted into 41,603 shares of the Company’s Series A Convertible Preferred stock (3,536,254 shares pre reverse split at $0.0386) as part of the $1,450,000 cash investment. The conversion of the four notes issued from March 27, 2015 to May 21, 2015, on June 12, 2015 will be treated as a troubled debt restructuring in accordance with FASB ASC 470-60-15 which defines troubled debt restructuring. A debtor that issues or otherwise grants an equity interest to a creditor to settle fully a payable shall account for the equity interest at its fair value. The difference between the fair value of the equity interest granted and the carrying amount of the payable settled shall be recognized as a gain on restructuring payables.

Warrant Liability

Warrant Liability	6 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Warrant Liability	NOTE 9 – WARRANT LIABILITY On December 31, 2012, the Company entered into an Investment Agreement, a Technology and Service Agreement, a Patent and Technology License Agreement and an Asset Purchase Agreement with VerifyMe on the same date entered into a Technology and Service Agreement with Zaah Technologies, Inc. (collectively with the VerifyMe agreements, the “Agreements”). Contemplated by those Agreements were warrant issuances by the Company for the purchase of the Company’s common stock. The 1,094,304 (post reverse split) warrants associated with these Agreements are subject to anti-dilution adjustments outlined in the Agreements. In accordance with FASB ASC 815, the warrants were classified as a liability in the total amount of $2.4 million at December 31, 2012. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2015 and December 31, 2014, the fair value of the warrant liability was $1,828,662 and $787,544. On January 1, 2014, the Company issued warrants to purchase 6,349,206 shares of the Company’s common stock as consideration for technology received from VerifyMe under to the Patent and Technology License Agreement dated December 31, 2012. The warrants are exercisable at $0.10 per share. The warrants are subject to anti-dilution adjustments outlined in the Agreement. In accordance with FASB ASC 815, the warrants were classified as a liability with an initial fair value of $444,000, which was immediately expensed as research and development costs. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2015 and December 31, 2014, the fair value of the warrant liability was $238,447 and $121,209. The Company made the payment of warrants to VerifyMe on a good faith basis, based on the assumption that the technology conveyed to the Company would be patentable and licensable. The Company had not reached a conclusion at that time that the technology would be patentable and licensable. As of June 12, 2015, the Company concluded that the technology received from VerifyMe is patentable and licensable, and that the Company was required to make, on January 1, 2015, an additional payment pursuant to Patent and Technology Agreement in the amount of $4,500,000, to be paid by issuing (i) a number of shares of common stock equal to (x) $4,500,000 divided by (y) a price which equals a 10% discount to the market price at the time of issuance and (ii) warrants to purchase an equal number of shares of common stock exercisable at a price of $0.10 per share. Based upon the share price of $0.04 per share, this would result in the issuance of approximately an additional 125 million shares of common stock and warrants to purchase an additional 125 million shares. The $4,500,000 was accrued at December 31, 2014. The number of warrants to be issued based on a stock price of $0.02 at December 31, 2014 was 250 million warrants. The warrants were valued at $4,892,089 using the Black-Scholes pricing model to calculate the grant-date fair value of the warrants with the following assumptions: no dividend yield, expected volatility of 229.1%, risk free interest rate of 1.65% and expected life of five years. In conjunction with the Recapitalization Transaction (see Note 6), the Company agreed that an additional $2,000,000 in exclusivity licensing fees was required to be paid and converted the $6,500,000 into Series B Convertible Preferred Stock. In addition, the fair value of the associated warrants was $1,867,417 as of June 12, 2015 and was recorded as additional paid in capital on conversion. The warrants associated with the notes payable (see Note 8) were revalued at June 12, 2015, based on the cashless conversion modification. The total fair value of those warrants was $40,000 and recorded as additional paid in capital on conversion.

Convertible Preferred Stock

Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Convertible Preferred Stock	NOTE 10 – CONVERTIBLE PREFERRED STOCK Subscription Agreement The Company entered into a Subscription Agreement with VerifyMe on January 31, 2013 (the “Subscription Agreement”). Under the terms of the Subscription Agreement, VerifyMe subscribed to purchase 33,333,333 shares of the Company’s Series A preferred stock (the “Preferred Stock”) and a warrant to purchase 33,333,333 shares of the Company’s common stock at an exercise price of $0.12 per share, for $1 million. At any time before January 31, 2015, VerifyMe had the right, but not the obligation, to require the Company to repurchase all, but not less than all, of the capital stock of the Company and warrants exercisable for capital stock of the Company held by VerifyMe in exchange for the price originally paid by VerifyMe therefore upon the occurrence of any of the following events:(i) the consummation of any bona fide business acquisition, (ii) the incurrence of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preference on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share. This right had not been exercised. In accordance with FASB ASC 480 and 815, the Preferred Stock was classified as permanent equity and was valued at $1 million at January 31, 2013. The conversion feature of the Preferred Stock is an embedded derivative, which is classified as a liability in accordance with FASB ASC 815 and was valued in accordance with FASB ASC 470 as a beneficial conversion feature at a fair value of $0 at June 12, 2015 and December 31, 2014. This was classified as an embedded derivative liability and a discount to Preferred Stock. Because the Preferred Stock can be converted at any time, the full amount of the original fair value was accreted and classified as a reduction to the discount on Preferred Stock and a deemed dividend distribution in the full amount of $1 million, in 2013. Previously on August 5, 2013 12,222,222 shares of Preferred Stock were converted into 12,222,222 shares of common stock. The Company has determined that the convertible preferred stock issuance in the June 12, 2015 Recapitalization Transaction does not meet the requirements of FASB ASC 480-10 for liability treatment and therefore has been classified as permanent equity. Additionally, it was determined that the economic characteristics of the beneficial conversion feature are clearly and closely related to the host, and is based on a fixed conversion rate into common shares and therefore does not require bifurcation. The Preferred Stock was converted into 248,366 shares of common stock (21,111,111 pre reverse split shares) shares of common stock (21,111,111 pre reverse split shares) on June 12, 2015 in conjunction with the Recapitalization Transaction (see Note 6). The warrants associated with the Preferred Stock were also classified as a liability since they are subject to anti-dilutive adjustments outlined in the warrant agreement and valued at a fair market value of $2,995,791 at January 31, 2013. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2015 and December 31, 2014, the fair value of the warrants was $1,115,395 and $494,939. On May 26, 2015, the Company amended its Amended and Restated Articles of Incorporation dated December 19, 2003 to establish the Series A Convertible Preferred Stock and authorized 441,938 shares (37,564,767 pre reverse split shares). The par value of the Series A Convertible Preferred Stock is $.001 and they are convertible currently at 20:1. These shares were issued as part of the cash investment section of the Restructuring Transaction (see Note 6). Also on May 26, 2015, the Company amended its Amended and Restated Articles of Incorporation dated December 19, 2003 to establish the Series B Convertible Preferred Stock and authorized 1 share (85 pre reverse split shares). The par value of the Series B Convertible Preferred Stock is $.001 and they are convertible currently at 8,496,732:1. These shares were issued to settle the $6.5 million of licensing fees due and the associated warrants as part of the Recapitalization Transaction (see Note 6). On June 12, 2015, the Company sold 389,668 Series A Convertible Preferred shares (33,121,777 pre reverse split shares) to an investor for $1,278,501. In addition, an officer and a stockholder received a total of 10,667 Series A Convertible Preferred shares (906,736 pre reverse split shares) for the forgiveness of previously accrued but unpaid compensation valued at $35,000. The Preferred Stock has a preference in liquidation that the holders of the Preferred Stock are to be paid out of assets available for distribution prior to holders of common stock. The Preferred Stockholders may cast the number of votes equal to the number of whole shares of common stock into which the shares of Preferred Stock can be converted. In addition, the Preferred Stockholders are to be paid dividends, based on the number of shares of Preferred Stock as if the shares had been converted to common shares, prior to the common stockholders receiving a dividend.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS Derivative Liabilities For purposes of determining whether certain instruments are derivatives for accounting treatment, the Company follows the accounting standard that provides guidance for determining whether an equity-linked financial instrument, or embedded feature, is indexed to an entity’s own stock. The standard applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative, and to any freestanding financial instruments that are potentially settled in an entity’s own common stock. Liabilities measured at fair value on a recurring basis are summarized as follows: Level 1 Level 2 Level 3 Total Derivative liability related to fair value of warrants $ — $ — $ 3,182,504 $ 3,182,504 Total $ — $ — $ 3,182,504 $ 3,182,504 The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs: Total Balance at January 1, 2015 $ 6,370,709 Conversion of notes payable, net of interest expense $ (33,943 ) Conversion of warrants related to licensing fees $ (1,867,417 ) Change in fair value of derivative liabilities (1,286,845 ) Balance at June 30, 2015 $ 3,182,504 The Company has no assets that are measured at fair value on a recurring basis. There were no assets or liabilities measured at fair value on a non-recurring basis during the three months and six months ended June 30, 2015. As of June 30, 2015, the Company’s outstanding warrants were treated as derivative liabilities and changes in the fair value were recognized in earnings. These common stock purchase warrants did not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes and the following assumptions: June 30, 2015 Annual Dividend Yield 0.0 % Expected Life (Years) 2.50 - 3.51 Risk-Free Interest Rate 1.01 % Expected Volatility 162.0% - 169.8 % Expected volatility was based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company’s expectations of future volatility over the expected term of these warrants. The Company had no reason to believe future volatility over the expected remaining life of these warrants was likely to differ materially from historical volatility. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants.

Stock Options

Stock Options	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stock Options	NOTE 13 – STOCK OPTIONS During 1999, the Board of Directors (“Board”) of the Company adopted, with the approval of the stockholders, a Stock Option Plan. In 2000, the Board superseded that plan and created a new Stock Option Plan, pursuant to which it is authorized to grant options to purchase up to 1.5 million shares of common stock. On December 17, 2003, the Board, with approval of the stockholders, superseded the 2000 plan and created the 2003 Stock Option Plan (the “2003 Plan”). Under the 2003 Plan the Company is authorized to grant options to purchase up to 18,000,000 shares of common stock to the Company’s employees, officers, directors, consultants, and other agents and advisors. The Plan is intended to permit stock options granted to employees under the Plan to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”). All options granted under the 2003 Plan, which are not intended to qualify as Incentive Stock Options, are deemed to be non-qualified options (“Non-Statutory Stock Options”). During 2013, the Board adopted a new omnibus incentive compensation plan (the “2013 Plan”) which will serve as the successor incentive compensation plan to the 2003 Plan, and will provide the Company with a comprehensive plan to design and structure grants of stock options, stock units, stock awards, stock appreciation rights and other stock-based awards for our employees, non-employee directors and certain consultants and advisors. The Board of Directors believes that the availability of (i) 20,000,000 new shares of our common stock, plus (ii) the 16,600,577 shares (post reverse-split) of our common stock available for issuance under the 2003 Plan, will be sufficient to meet the objective. As of June 30, 2015, there are 1,470,012 options (post reverse-split) that have been issued under the Plans, and 36,529,988 options that are available to be issued under the Plans. There are an additional 484,706 options that are have been issued that are not included in the Plans. The 2013 Plan is administered by a committee of the Board (“Stock Option Committee”) which determines the persons to whom awards will be granted, the number of awards to be granted and the specific terms of each grant, including the vesting thereof, subject to the provisions of the plan. In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). The aggregate fair market value (determined at the time of the grant) of stock for which an employee may exercise Incentive Stock Options under all plans of the company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be Non-Statutory Stock Options, including prices, duration, transferability and limitations on exercise. The Company issued Non-Statutory Stock Options pursuant to contractual agreements with non-employees. Options granted under the agreements are expensed when the related service or product is provided. Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value represent management’s best estimates and involve inherent uncertainties and judgments. On June 11, 2015, the Company issued options to purchase an aggregate of 1,225,000 shares of the Company’s common stock (104,125,000 pre reverse-split) at an exercise price of $0.85 per share, with a term of five years, to three employees and two members of the Board of Directors. The fair value of options issued was $993,083. These options were valued using the Black-Scholes option pricing model to calculate the grant-date fair value of the options, with the following assumptions: no dividend yield, expected volatility of 176.6%, risk-free interest rate of 1.74% to 1.75% and expected option life of five years. The options are being expensed over the vesting terms for the employees and over the board members’ remaining service terms as that is shorter than the vesting terms. For the three and six months ended June 30, 2015 the company expensed $88,928 and $34,093 with respect to the options. The following tables summarize non-employee stock option/warrant activity of the Company since December 31, 2014: Option/Warrant Exercise Weighted Average Outstanding, December 31, 2014 1,425,481 $0.85 to $12.75 $ 8.50 Granted — — — Exercised (49,412 ) 0.85 - 8.50 — Expired — — — Outstanding, June 30, 2015 1,376,069 $0.85 to $12.75 $ 8.66 Exercisable, June 30, 2015 1,376,069 $0.85 to $12.75 $ 8.66 Weighted Average Remaining Life, Exercisable, June 30, 2015 (years) 5.2 A summary of incentive stock option transactions for employees since December 31, 2014 is as follows: Option/Warrant Exercise Weighted Average Outstanding, December 31, 2014 633,725 $ 4.25 - $12.75 $ 4.25 Granted 1,225,000 0.85 — Exercised — — — Expired/Returned (176,471 ) 4.25 - 12.75 — Outstanding, June 30, 2015 1,682,255 $ 4.25 to $12.75 $ 2.00 Exercisable, June 30, 2015 528,824 $ 4.25 to $12.75 $ 4.22 Weighted Average Remaining Life, Exercisable, June 30, 2015 (years) 8.1

Operating Leases

Operating Leases	6 Months Ended
	Jun. 30, 2015
Leases [Abstract]
Operating Leases	NOTE 14 – OPERATING LEASES For the three and six months ended June 30, 2015, total rent expense under leases amounted to $12,642 and $32,011. For the three and six months ended June 30, 2014, total rent expense under leases amounted to $17,766 and $35,493. At June 30, 2015, the Company was obligated under various non-cancelable operating lease arrangements for property as follows: 2015 37,926 2016 31,605 $ 69,531

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 15 – RELATED PARTY TRANSACTIONS At June 12, 2015, three stockholders of the Company held $317,000 of the senior secured convertible notes payable and were owed accrued interest of $42,713. The notes and accrued interest were converted into 234,735 shares of common stock (19,952,489 pre reverse split shares) as described in Note 7 and 8.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 16 – SUBSEQUENT EVENTS On July 9, 2015, the Company hired a Chief Operating Officer (“COO”). The COO will receive 375,000 (31,875,000 pre reverse split) options to purchase shares of common stock of the Company, with an exercise price of $0.85 ($0.01 pre reverse split) and valued at $1,502,219. The options will vest quarterly over three years. The fair value of the options was valued using the Black-Scholes option pricing model with the following assumptions: no dividend yield, expected volatility of 180.1%, risk free interest rate of 1.58% and expected life of 5 years. In addition, the COO will receive 225,000 (19,125,000 pre reverse split) shares of restricted stock, vesting over a three-year period, with one-third vesting the first year and 1/12 vesting ratably on a quarterly basis thereafter. The restricted stock was valued at fair value of $918,000 based on the closing stock price of $4.08 on July 9, 2015. On July 23, 2015, the Company completed a 1-for-85 reverse stock split of its outstanding common and preferred stock, as further described in Note 1 above. On August 10, 2015, the Company agreed to issue the Chief Financial Officer 20,000 Restricted Stock Units (“RSU’s”) vesting over 6 months, 100,000 RSU’s vesting annually over 3 years, and 200,000 stock options vesting annually over 3 years. The RSU’s were valued at a fair value of $727,020 based on the closing stock price of $5.77 per share on August 10, 2015. The options were valued at fair value of $1,107,857, using the Black-Scholes option pricing model with the following assumptions: no dividend yield, expected volatility of 182.2%, risk free rate interest rate of 1.62% and expected life of 5 years.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Nature of the Business	Nature of the Business On July 14, 2015, LaserLock Technologies, Inc. changed its name to VerifyMe, Inc. (the “Company”), effective July 23, 2015. The Company was incorporated in the State of Nevada on November 10, 1999. The Company is based in New York, NY and its common stock is traded on the OTCQB under the ticker symbol “LLTI.D”. A high-tech solutions company in the field of authenticating people and products, the Company offers state-of-the-art solutions to combat identity fraud and counterfeiting utilizing multi-factor authentication and a suite of security pigments for governments, health care providers, the gaming industry, the financial services industry and high-end retailers. The Company invests in developing new proprietary color shifting inks that it believes will allow it to penetrate broader markets and result in increased revenues. The Company refines its technologies and their applications, and now has what it believes to be one of the most cost effective and efficient authentication technologies available. Its most recent technology takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in numerous potential new applications ranging from credit cards to drivers licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technologies can also be used to protect DVDs, apparel, pharmaceuticals, and virtually any other physical product. The Company’s digital solution is a multi-platform (iOS and Android) strong authentication solution that integrates biometrics and geo-location tagging. The solution completely eliminates passwords and the inherently weak security they provide. The solution also removes the user complexity associated with having to manage many complex passwords. The solution can be delivered either as a high availability cloud service, managed by the Company, or as a licensed software product for operation on the client’s premises. The solution integrates three independent authentication factors – something you have (for instance a smartphone), something you know (for instance a color gesture swipe) and something you are (for instance your facial geometry) - into a simple, fast, intuitive solution. The system can also accurately determine the precise location of the individual using a variety of mechanisms including GPS, cell tower triangulation, IP or WIFI address. Because the solution incorporates biometrics it completely eliminates the possibility that users might share their authentication credentials. The combination of biometrics and geolocation provides extremely strong transactional evidence, making it nearly impossible for an end-user to refute having been part of a transaction. The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to operationalize the Company’s current technology.
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on form 10-K for the year ended December 31, 2014 as filed with the SEC. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.
Reverse Stock Split and Amended and Restated Certificate of Incorporation	Reverse Stock Split and Amended and Restated Certificate of Incorporation On May 28, 2015, the stockholders voted to allow a reverse stock split between 1-for-40 and 1-for-100. On July 23, 2015, the Company completed a 1-for-85 reverse stock split of its outstanding common and preferred stock. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented. In addition, the reverse stock split resulted in an adjustment in the number of shares of common stock issuable upon conversion of the convertible preferred stock on a 1-for-85 ratio. In addition, the Company adopted an Amended and Restated Certificate of Incorporation, which provides that the Company’s authorized capital stock consists of 675 million shares of common stock, $0.001 par value per share, 37,564,767 million shares of Series A Convertible Preferred Stock, $0.001 par value per share and 85 shares of Series B Convertible Preferred Stock, $0.001 par value per share.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Comprehensive Income	Comprehensive Income The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss).
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of accounts receivable, accounts payable and accrued expenses, warrant liability and notes payable. The carrying value of accounts receivable, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures Level 1: Quoted market prices in active markets for identical assets or liabilities Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs that are not corroborated by market data The level in the fair value within which a fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.
Concentration of Credit Risk Involving Cash and Cash Equivalents	Concentration of Credit Risk Involving Cash and Cash Equivalents The Company’s cash and cash equivalents are held at one financial institution. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.
Inventory	Inventory Inventory principally consists of penlights and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.
Property and Equipment	Property and Equipment Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operation
Patents and Trademark	Patents and Trademark The Company has filed eleven patent applications relating to the Company technology. Currently we have 7 U.S. patents, 4 U.S. applications pending for allowance, and 5 foreign applications pending for allowance. The Company has also purchased a trademark. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be 17 to 20 years.
Long-Lived Assets	Long-Lived Assets The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.
Deferred Financing Costs	Deferred Financing Costs Costs incurred in securing long-term debt are deferred and amortized, as a charge to interest expense, over the term of the related debt. In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50 “Debt – Modification and Extinguishments.”
Convertible Notes Payable	Convertible Notes Payable Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature (BCF) as a debt discount, which is then accreted to interest expense over the life of the related debt using the straight-line method which approximates the effective interest method.
Derivative Instruments	Derivative Instruments The Company evaluates its convertible debt, preferred stock, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Topic 480 of the FASB ASC and Topic 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative, if required to be bifurcated, is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified as liabilities at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
Revenue Recognition	Revenue Recognition In accordance with Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition (Codified in FASB ASC 605), the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process.
Income Taxes	Income Taxes The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Tax years from 2011 through 2014 remain subject to examination by major tax jurisdictions.
Stock-based Payments	Stock-based Payments The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Non-employee equity based payments are recorded as an expense over the service period, as if the Company had paid cash for the services. At the end of each financial reporting period, prior to vesting or prior to the completion of the services, the fair value of the equity based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the equity based payments are fully vested or the service completed.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. Advertising costs were approximately $100 and $258 for the three and six months ended June 30, 2015 and $25,955 and $53,238 for the six months ended June 30, 2014 and are included in sales and marketing expenses.
Research and Development Costs	Research and Development Costs In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the three and six months ended June 30, 2015 were $2,016,000 and $2,136,386 and $83,887 and $948,616 for the three and six months ended June 30, 2014.
Basic and Diluted Net Income per Share of Common Stock	Basic and Diluted Net Income per Share of Common Stock The Company follows FASB ASC 260 when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Basic net income per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted net income per common share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive, i.e., the exercise prices of the outstanding stock options were greater than the market price of the common stock. Anti-dilutive common stock equivalents, which were excluded from the calculation of number of dilutive common stock equivalents, amounted to 2,018,618 shares for the three and six months ended June 30, 2014.
Segment Information	Segment Information The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with ASC 280, Segment Reporting, the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by ASC 280 can be found in the financial statements.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements As of June 30, 2015 and for the three and six months then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted As of June 30, 2015, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company’s financial statements through 2017.
Reclassifications	Reclassifications Certain amounts in 2014 statement of operations have been reclassified in order for them to conform with the 2015 presentation.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Equipment	Equipment consists of the following: June 30, December 31, 2015 2014 Furniture and Fixtures $ 219,871 $ 219,871 Equipment 16,155 16,155 236,026 236,026 Less: Accumulated depreciation 195,832 161,205 $ 40,194 $ 74,821

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at June 30, 2015 and December 31, 2014: June 30, December 31, 2015 2104 Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015 — $ 114,000 Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due) — 50,000 Notes payable; interest at 8% per annum, principal and accrued interest due at December 1, 2014 (past due) — 650,000 Notes payable; interest at 5% and 8% per annum, principal and accrued interest due at April 2015 — 123,000 Notes payable; interest at 5% per annum, principal and accrued interest due at June 10, 2015 — — Notes payable; interest at 8% per annum, principal and accrued interest due at June 25, 2015 — — Less: Debt discount — (10,447 ) — 926,553 Less: Current portion — 926,553 $ — $ —

Fair Value of Financial Instr27

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Liabilities Measured at Fair Value on a Recurring Basis	Liabilities measured at fair value on a recurring basis are summarized as follows: Level 1 Level 2 Level 3 Total Derivative liability related to fair value of warrants $ — $ — $ 3,182,504 $ 3,182,504 Total $ — $ — $ 3,182,504 $ 3,182,504
Fair Value Measurements within Fair Value Hierarchy of Derivative Liabilities Using Level 3 Inputs	The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs: Total Balance at January 1, 2015 $ 6,370,709 Conversion of notes payable, net of interest expense $ (33,943 ) Conversion of warrants related to licensing fees $ (1,867,417 ) Change in fair value of derivative liabilities (1,286,845 ) Balance at June 30, 2015 $ 3,182,504
Schedule of Common Stock Purchase Warrants Valuation Assumptions	As of June 30, 2015, the Company’s outstanding warrants were treated as derivative liabilities and changes in the fair value were recognized in earnings. These common stock purchase warrants did not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes and the following assumptions: June 30, 2015 Annual Dividend Yield 0.0 % Expected Life (Years) 2.50 - 3.51 Risk-Free Interest Rate 1.01 % Expected Volatility 162.0% - 169.8 %
Stockholders' Equity	NOTE 12 – STOCKHOLDERS’ EQUITY On January 1, 2014, under the terms of the Patent and Technology License Agreement, the Company issued 6,349,206 shares of common stock to VerifyMe, in addition to the warrants described in Note 9 above. The shares were issued in payment for the technology received. Under the agreement, $400,000 worth of the Company’s common stock was to be paid by the Company to VerifyMe at a 10% discount to the market at time of payment. The closing price was $0.07 per share discounted 10% to $0.063. The $400,000 payment divided by the $0.063 per share resulted in 6,349,206 shares (pre reverse-split) to be issued. The entire $400,000 payment was expensed to research and development. On June 12, 2015, the Company sold 304,785 shares of common stock (25,906,735 pre reverse split shares) and raised $50,000. During the three months ended June 30, 2015, one stockholder exercised 2,353 warrants and received 2,353 shares of the Company’s common stock in a cashless exercise. On June 11, 2015, the Company issued 525,000 restricted stock units (44,625,000 pre reverse-split units) to two officers of the Company. The restricted stock units were valued at the closing stock price of $0.01 on June 11, 2015, at $446,250, fair value. These restricted stock units are being expensed over the vesting terms. For the three and six months ended June 30, 2015, the Company expensed $6,198 related to the restricted stock units.

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Schedule of Incentive Stock Option Transactions for Employees	The following tables summarize non-employee stock option/warrant activity of the Company since December 31, 2014: Option/Warrant Exercise Weighted Average Outstanding, December 31, 2014 1,425,481 $0.85 to $12.75 $ 8.50 Granted — — — Exercised (49,412 ) 0.85 - 8.50 — Expired — — — Outstanding, June 30, 2015 1,376,069 $0.85 to $12.75 $ 8.66 Exercisable, June 30, 2015 1,376,069 $0.85 to $12.75 $ 8.66 Weighted Average Remaining Life, Exercisable, June 30, 2015 (years) 5.2
Schedule of Non-employee Stock Option/Warrant Activity	A summary of incentive stock option transactions for employees since December 31, 2014 is as follows: Option/Warrant Exercise Weighted Average Outstanding, December 31, 2014 633,725 $ 4.25 - $12.75 $ 4.25 Granted 1,225,000 0.85 — Exercised — — — Expired/Returned (176,471 ) 4.25 - 12.75 — Outstanding, June 30, 2015 1,682,255 $ 4.25 to $12.75 $ 2.00 Exercisable, June 30, 2015 528,824 $ 4.25 to $12.75 $ 4.22 Weighted Average Remaining Life, Exercisable, June 30, 2015 (years) 8.1

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended
	Jun. 30, 2015
Leases [Abstract]
Schedule of Non-cancelable Operating Lease Arrangements for Property	At June 30, 2015, the Company was obligated under various non-cancelable operating lease arrangements for property as follows: 2015 37,926 2016 31,605 $ 69,531

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Additional Information (Detail)		3 Months Ended		6 Months Ended
		Jun. 30, 2015USD ($)Patents$ / sharesshares	Jun. 30, 2014USD ($)shares	Jun. 30, 2015USD ($)PatentsSegmentInstitution$ / sharesshares	Jun. 30, 2014USD ($)shares	May. 28, 2015	Dec. 31, 2014$ / sharesshares
Schedule Of Significant Accounting Policies [Line Items]
Reverse stock split ratio		85		85
Common stock, shares authorized | shares		675,000,000		675,000,000			675,000,000
Common stock, par value | $ / shares		$ 0.001		$ 0.001			$ 0.001
Number of financial institutions at which company's cash and cash equivalents are held | Institution				1
Depreciation method of property and equipment				Straight-line method
Research and development costs | $	[1]	$ 2,016,000	$ 83,887	$ 2,136,386	$ 948,616
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares			2,018,618		2,018,618
Number of operating segment | Segment				1
Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents filed				11
Number of patents issued		7		7
Amortization method of patents				Straight-line basis
Patents and Trademark | UNITED STATES
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents pending for allowance.				4
Patents and Trademark | Foreign Countries
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents pending for allowance.				5
Sales and marketing expenses
Schedule Of Significant Accounting Policies [Line Items]
Advertising costs | $		$ 100	$ 25,955	$ 258	$ 53,238
Series A Convertible Preferred Stock
Schedule Of Significant Accounting Policies [Line Items]
Preferred stock, shares authorized | shares		37,564,767		37,564,767			75,000,000
Preferred stock, par value | $ / shares		$ 0.001		$ 0.001			$ 0.001
Series B Convertible Preferred Stock
Schedule Of Significant Accounting Policies [Line Items]
Preferred stock, shares authorized | shares		85		85			0
Preferred stock, par value | $ / shares		$ 0.001		$ 0.001			$ 0.001
Convertible Preferred Stock
Schedule Of Significant Accounting Policies [Line Items]
Common stock issuable upon conversion of convertible preferred stock				85
Minimum
Schedule Of Significant Accounting Policies [Line Items]
Reverse stock split ratio						40
Estimated useful lives of property and equipment				5 years
Minimum | Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Estimated lives of patents				17 years
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Reverse stock split ratio						100
Estimated useful lives of property and equipment				7 years
Maximum | Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Estimated lives of patents				20 years
[1]	includes shares based compensation of $2,000,000 for the three and six months ended June 30, 2015 and $0 and $400,000 for the three and six months ended June 30, 2014, related to licensing agreements.

Property and Equipment - Equipm

Property and Equipment - Equipment (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment, Net [Abstract]
Furniture and Fixtures	$ 219,871	$ 219,871
Equipment	16,155	16,155
Property, Plant and Equipment, Gross, Total	236,026	236,026
Less: Accumulated depreciation	195,832	161,205
Capital equipment, net of accumulated depreciation of $195,832 and $161,205 as of June 30, 2015 and December 31, 2014	$ 40,194	$ 74,821

Plant and Equipment - Additiona

Plant and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment, Net [Abstract]
Depreciation of property and equipment	$ 17,313	$ 17,313	$ 34,626	$ 34,626

Patents and Trademark - Additio

Patents and Trademark - Additional Information (Detail) - Patents and Trademark	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)Patents	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)Patents	Jun. 30, 2014USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of provisional patents filed			11
Amortization method of patents			Straight-line basis
Capitalized patent costs | $	$ 100	$ 0	$ 100	$ 0
Amortization expense | $	$ 4,203	$ 3,277	$ 8,406	$ 6,554
Number of patents	7		7
Number of pending applications for patents	4		4
Foreign [Member]
Finite-Lived Intangible Assets [Line Items]
Number of pending applications for patents	5		5
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated lives of patents			17 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated lives of patents			20 years
Anti Counterfeiting Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Number of provisional patents filed			11

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 0	$ 0	$ 0	$ 0
Unrecognized tax benefits					$ 0
Interest or penalties related to unrecognized tax benefits					$ 0
Change in unrecognized tax benefits	0		0
Accrual for uncertain tax positions	$ 0		$ 0

Recapitalization Transaction -

Recapitalization Transaction - Additional Information (Detail) - USD ($)	Jun. 12, 2015	Jun. 30, 2015	Dec. 31, 2014	Aug. 05, 2013
Restructuring Cost and Reserve [Line Items]
Amount of outstanding notes converted in to common stock shares		$ 802,453
Shares of common stock shares issued on conversion				12,222,222
Cash investment of OPC		$ 1,278,501
Common stock, shares issued	304,785	5,852,646	3,969,106
Cash investment of private investor	$ 50,000	$ 50,000
OPC Partners LLC
Restructuring Cost and Reserve [Line Items]
Cash investment of OPC	$ 1,450,000
Private Investor
Restructuring Cost and Reserve [Line Items]
Cash investment of private investor		$ 50,000
Pre Reverse Split
Restructuring Cost and Reserve [Line Items]
Outstanding common stock warrant		4,000,000
Common stock shares issued on conversion of warrant		4,000,000
Shares of common stock shares issued on conversion	21,111,111	21,111,111
Common stock, shares issued	25,906,735
Pre Reverse Split | Private Investor
Restructuring Cost and Reserve [Line Items]
Common stock, shares issued		25,906,736
Series B Convertible Preferred Stock
Restructuring Cost and Reserve [Line Items]
Preferred stock, shares authorized		85	0
Series A Convertible Preferred Stock
Restructuring Cost and Reserve [Line Items]
Preferred stock, shares authorized		37,564,767	75,000,000
Series A Convertible Preferred Stock | OPC Partners LLC
Restructuring Cost and Reserve [Line Items]
Cash investment of OPC		$ 1,450,000
Series A Convertible Preferred Stock | Pre Reverse Split | OPC Partners LLC
Restructuring Cost and Reserve [Line Items]
Preferred stock, shares authorized		37,564,767
Patent and Technology License Termination Agreement
Restructuring Cost and Reserve [Line Items]
Additional payment for patent and technology		$ 4,500,000
Payments under license		$ 2,000,000
Patent and Technology License Termination Agreement | Series B Convertible Preferred Stock
Restructuring Cost and Reserve [Line Items]
Preferred stock, shares authorized		85
Convertible Note | Pre Reverse Split
Restructuring Cost and Reserve [Line Items]
Amount of outstanding notes converted in to common stock shares		$ 1,156,545
Common stock shares issued on conversion of debt (in shares)		64,258,029

Senior Secured Convertible No36

Senior Secured Convertible Notes Payable -Related Parties - Additional Information (Detail) - USD ($)	Jun. 12, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Debt Instrument [Line Items]
Amount of notes converted into common stock shares				$ 802,453
Gain on extinguishment of debt		$ 351,918	$ (82,000)	$ 351,918	$ (82,000)
10% Senior Secured Convertible Promissory Notes
Debt Instrument [Line Items]
Amount of notes converted into common stock shares			216,249
Accrued interest of notes converted into common stock shares			$ 208,339
Common stock shares issued on conversion of debt	154,184		8,448,519
Gain on extinguishment of debt	$ 85,489		$ (82,000)
Outstanding principal balance on notes	114,000
Accrued interest	$ 118,775
Pre reverse split common stock	13,105,662
Pre reverse split common stock share price	$ 0.018
Total gain on conversion of notes	$ 103,456
Gain on conversion of notes recorded as additional paid in capital	$ 17,967

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Less: Debt discount		$ (10,447)
Notes payable		926,553
Notes payable		926,553
Less: Current portion		812,553
Long-term portion	$ 0	0
Adjustment
Debt Instrument [Line Items]
Less: Current portion		926,553
Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015
Debt Instrument [Line Items]
Notes payable		114,000
Notes payable		114,000
Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)
Debt Instrument [Line Items]
Notes payable		50,000
Notes payable		50,000
Notes payable; interest at 8% per annum; principal and accrued interest due at December 1, 2014 (past due)
Debt Instrument [Line Items]
Notes payable		650,000
Notes payable		650,000
Notes payable, interest at 5% and 8% per annum; principal and interest due April 2015
Debt Instrument [Line Items]
Notes payable		123,000
Notes payable		$ 123,000

Notes Payable - Schedule of N38

Notes Payable - Schedule of Notes Payable (Parenthetical) (Detail)	Jun. 30, 2015	Dec. 31, 2014
Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015
Debt Instrument [Line Items]
Interest rate	10.00%	10.00%
Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)
Debt Instrument [Line Items]
Interest rate	8.00%	8.00%
Notes payable; interest at 8% per annum; principal and accrued interest due at December 1, 2014 (past due)
Debt Instrument [Line Items]
Interest rate	8.00%	8.00%
Notes payable, interest at 5% and 8% per annum; principal and interest due April 2015
Debt Instrument [Line Items]
Interest rate	5.00%	8.00%
Notes payable; interest at 5% per annum, principal and accrued interest due at June 10, 2015
Debt Instrument [Line Items]
Interest rate	5.00%
Notes payable; interest at 8% per annum, principal and accrued interest due at June 25, 2015
Debt Instrument [Line Items]
Interest rate	8.00%

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($)	Jun. 12, 2015	May. 21, 2015	Mar. 27, 2015	Mar. 15, 2015	Feb. 10, 2015	Dec. 05, 2014	Sep. 08, 2014	Aug. 14, 2014	Aug. 12, 2014	Aug. 05, 2014	Jun. 10, 2014	Apr. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Debt Instrument [Line Items]
Note payable balance																		$ 812,553
Accrued interest	$ 42,713
Gain on the extinguishment of debt													$ 351,918	$ (82,000)		$ 351,918	$ (82,000)
Proceeds from issuance of notes payable																159,542	250,000
Note payable balance																		812,553
Accrued interest	42,713
Proceeds from issuance of notes payable																159,542	250,000
Accumulated discount, notes payable (in dollars)																		10,447
Interest expense													24,904	13,121		55,154	24,028
Gain on the extinguishment of debt													351,918	(82,000)		351,918	(82,000)
Cash investment by OPC																1,278,501
Accumulated discount, notes payable (in dollars)																		10,447
Interest expense													$ 24,904	$ 13,121		$ 55,154	$ 24,028
Warrant | June 10, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	8,113
Warrant | August 5, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	5,151
Warrant | August 12, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	2,575
Warrant | August 14, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	5,153
Warrant | September 8, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	7,725
Warrant | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Fair value of warrant liability	5,226
OPC Partners LLC
Debt Instrument [Line Items]
Cash investment by OPC	$ 1,450,000
Common Stock
Debt Instrument [Line Items]
Shares issued on conversion of debt (in shares)	234,735															755,977
Shares issued on conversion of debt (in shares)	234,735															755,977
Notes Payable
Debt Instrument [Line Items]
Note payable balance	$ 134,542
Accrued interest	$ 2,271
Shares issued on conversion of debt (in shares)	41,603
Pre reverse split shares issued on conversion of debt (in shares)	3,536,254
Pre reverse split share price	$ 0.0386
Note payable balance	$ 134,542
Accrued interest	$ 2,271
Shares issued on conversion of debt (in shares)	41,603
Pre reverse split shares issued on conversion of debt (in shares)	3,536,254
Pre reverse split share price	$ 0.0386
Notes Payable | June 10, 2014
Debt Instrument [Line Items]
Note payable balance	$ 250,000
Accrued interest	$ 20,263
Shares issued on conversion of debt (in shares)	176,471
Pre reverse split shares issued on conversion of debt (in shares)	15,000,000
Pre reverse split share price	$ 0.018
Note payable balance	$ 250,000
Accrued interest	$ 20,263
Shares issued on conversion of debt (in shares)	176,471
Pre reverse split shares issued on conversion of debt (in shares)	15,000,000
Pre reverse split share price	$ 0.018
Gain recorded in additional paid in capital	$ 120,117
Interest expense																		$ 34,222
Interest rate, notes payable																		8.00%
Interest expense																		$ 34,222
Interest rate, notes payable																		8.00%
Notes Payable | August 5, 2014
Debt Instrument [Line Items]
Note payable balance	100,000
Accrued interest	$ 6,828
Shares issued on conversion of debt (in shares)	69,797
Pre reverse split shares issued on conversion of debt (in shares)	5,932,724
Pre reverse split share price	$ 0.018
Gain on the extinguishment of debt	$ 47,479
Note payable balance	100,000
Accrued interest	$ 6,828
Shares issued on conversion of debt (in shares)	69,797
Pre reverse split shares issued on conversion of debt (in shares)	5,932,724
Pre reverse split share price	$ 0.018
Interest expense																		$ 22,914
Interest rate, notes payable																		8.00%
Gain on the extinguishment of debt	$ 47,479
Interest expense																		$ 22,914
Interest rate, notes payable																		8.00%
Notes Payable | August 12, 2014
Debt Instrument [Line Items]
Note payable balance	50,000
Accrued interest	$ 3,370
Shares issued on conversion of debt (in shares)	34,843
Pre reverse split shares issued on conversion of debt (in shares)	2,961,644
Pre reverse split share price	$ 0.018
Gain on the extinguishment of debt	$ 23,720
Note payable balance	50,000
Accrued interest	$ 3,370
Shares issued on conversion of debt (in shares)	34,843
Pre reverse split shares issued on conversion of debt (in shares)	2,961,644
Pre reverse split share price	$ 0.018
Interest expense																		$ 17,455
Interest rate, notes payable																		8.00%
Gain on the extinguishment of debt	$ 23,720
Interest expense																		$ 17,455
Interest rate, notes payable																		8.00%
Notes Payable | August 14, 2014
Debt Instrument [Line Items]
Note payable balance	100,000
Accrued interest	$ 6,697
Shares issued on conversion of debt (in shares)	69,657
Pre reverse split shares issued on conversion of debt (in shares)	5,920,852
Pre reverse split share price	$ 0.018
Gain on the extinguishment of debt	$ 47,421
Note payable balance	100,000
Accrued interest	$ 6,697
Shares issued on conversion of debt (in shares)	69,657
Pre reverse split shares issued on conversion of debt (in shares)	5,920,852
Pre reverse split share price	$ 0.018
Interest expense																		$ 32,274
Interest rate, notes payable																		8.00%
Gain on the extinguishment of debt	$ 47,421
Interest expense																		$ 32,274
Interest rate, notes payable																		8.00%
Notes Payable | September 8, 2014
Debt Instrument [Line Items]
Note payable balance	150,000
Accrued interest	$ 9,223
Shares issued on conversion of debt (in shares)	103,991
Pre reverse split shares issued on conversion of debt (in shares)	8,839,269
Pre reverse split share price	$ 0.018
Gain on the extinguishment of debt	$ 70,766
Note payable balance	150,000
Accrued interest	$ 9,223
Shares issued on conversion of debt (in shares)	103,991
Pre reverse split shares issued on conversion of debt (in shares)	8,839,269
Pre reverse split share price	$ 0.018
Interest expense																		$ 44,140
Interest rate, notes payable																		8.00%
Gain on the extinguishment of debt	$ 70,766
Interest expense																		$ 44,140
Interest rate, notes payable																		8.00%
Notes Payable | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Note payable balance	100,000
Accrued interest	$ 3,689
Shares issued on conversion of debt (in shares)	67,637
Pre reverse split shares issued on conversion of debt (in shares)	5,749,163
Pre reverse split share price	$ 0.018
Gain on the extinguishment of debt	$ 46,084
Note payable balance	100,000
Accrued interest	$ 3,689
Shares issued on conversion of debt (in shares)	67,637
Pre reverse split shares issued on conversion of debt (in shares)	5,749,163
Pre reverse split share price	$ 0.018
Interest expense															$ 10,447
Interest rate, notes payable															8.00%
Gain on the extinguishment of debt	$ 46,084
Interest expense															$ 10,447
Interest rate, notes payable															8.00%
Notes Payable | Warrant
Debt Instrument [Line Items]
Expected dividend yield																0.00%
Notes Payable | Warrant | June 10, 2014
Debt Instrument [Line Items]
Expected volatility											248.20%
Risk-free interest rate											1.67%
Expected warrant term											5 years
Proceeds from issuance of notes payable											$ 250,000
Number of common stock called by warrants (in shares)											1,000,000
Exercise price (in dollars per share)											$ 0.10
Fair value of warrant liability											$ 39,650
Proceeds from issuance of notes payable											$ 250,000
Number of common stock called by warrants (in shares)											1,000,000
Exercise price (in dollars per share)											$ 0.10
Expected volatility											248.20%
Risk-free interest rate											1.67%
Expected warrant term											5 years
Accumulated discount, notes payable (in dollars)											$ 34,222
Accumulated discount, notes payable (in dollars)											$ 34,222
Notes Payable | Warrant | August 5, 2014
Debt Instrument [Line Items]
Expected volatility										233.80%
Risk-free interest rate										1.67%
Expected warrant term										5 years
Proceeds from issuance of notes payable										$ 100,000
Number of common stock called by warrants (in shares)										600,000
Exercise price (in dollars per share)										$ 0.05
Fair value of warrant liability										$ 29,725
Proceeds from issuance of notes payable										$ 100,000
Number of common stock called by warrants (in shares)										600,000
Exercise price (in dollars per share)										$ 0.05
Expected volatility										233.80%
Risk-free interest rate										1.67%
Expected warrant term										5 years
Accumulated discount, notes payable (in dollars)										$ 22,914
Accumulated discount, notes payable (in dollars)										$ 22,914
Notes Payable | Warrant | August 12, 2014
Debt Instrument [Line Items]
Expected volatility									233.80%
Risk-free interest rate									1.67%
Expected warrant term									5 years
Proceeds from issuance of notes payable									$ 50,000
Number of common stock called by warrants (in shares)									300,000
Exercise price (in dollars per share)									$ 0.05
Fair value of warrant liability									$ 26,817
Proceeds from issuance of notes payable									$ 50,000
Number of common stock called by warrants (in shares)									300,000
Exercise price (in dollars per share)									$ 0.05
Expected volatility									233.80%
Risk-free interest rate									1.67%
Expected warrant term									5 years
Accumulated discount, notes payable (in dollars)									$ 17,455
Accumulated discount, notes payable (in dollars)									$ 17,455
Notes Payable | Warrant | August 14, 2014
Debt Instrument [Line Items]
Expected volatility								233.80%
Risk-free interest rate								1.67%
Expected warrant term								5 years
Proceeds from issuance of notes payable								$ 100,000
Number of common stock called by warrants (in shares)								600,000
Exercise price (in dollars per share)								$ 0.05
Fair value of warrant liability								$ 47,676
Proceeds from issuance of notes payable								$ 100,000
Number of common stock called by warrants (in shares)								600,000
Exercise price (in dollars per share)								$ 0.05
Expected volatility								233.80%
Risk-free interest rate								1.67%
Expected warrant term								5 years
Accumulated discount, notes payable (in dollars)								$ 32,274
Accumulated discount, notes payable (in dollars)								$ 32,274
Notes Payable | Warrant | September 8, 2014
Debt Instrument [Line Items]
Expected volatility							233.80%
Risk-free interest rate							1.67%
Expected warrant term							5 years
Proceeds from issuance of notes payable							$ 150,000
Number of common stock called by warrants (in shares)							900,000
Exercise price (in dollars per share)							$ 0.05
Fair value of warrant liability							$ 62,544
Proceeds from issuance of notes payable							$ 150,000
Number of common stock called by warrants (in shares)							900,000
Exercise price (in dollars per share)							$ 0.05
Expected volatility							233.80%
Risk-free interest rate							1.67%
Expected warrant term							5 years
Accumulated discount, notes payable (in dollars)							$ 44,140
Accumulated discount, notes payable (in dollars)							$ 44,140
Notes Payable | Warrant | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Expected volatility							229.00%
Risk-free interest rate							1.68%
Expected warrant term							5 years
Proceeds from issuance of notes payable							$ 100,000
Number of common stock called by warrants (in shares)							600,000
Exercise price (in dollars per share)							$ 0.05
Fair value of warrant liability							$ 11,812
Proceeds from issuance of notes payable							$ 100,000
Number of common stock called by warrants (in shares)							600,000
Exercise price (in dollars per share)							$ 0.05
Expected volatility							229.00%
Risk-free interest rate							1.68%
Expected warrant term							5 years
Accumulated discount, notes payable (in dollars)							$ 10,447
Accumulated discount, notes payable (in dollars)							10,447
Notes Payable | Warrant | Debt Instrument Date December 2014 | During the issuance
Debt Instrument [Line Items]
Accumulated discount, notes payable (in dollars)							10,563
Accumulated discount, notes payable (in dollars)							$ 10,563
Notes Payable | Stockholder
Debt Instrument [Line Items]
Note payable balance	23,000
Accrued interest	$ 609
Shares issued on conversion of debt (in shares)	15,418
Pre reverse split shares issued on conversion of debt (in shares)	1,310,510
Pre reverse split share price	$ 0.018
Proceeds from issuance of notes payable						$ 23,000
Note payable balance	$ 23,000
Accrued interest	$ 609
Shares issued on conversion of debt (in shares)	15,418
Pre reverse split shares issued on conversion of debt (in shares)	1,310,510
Pre reverse split share price	$ 0.018
Gain recorded in additional paid in capital	$ 10,493
Proceeds from issuance of notes payable						$ 23,000
Interest rate, notes payable						5.00%
Note due date						Apr. 5, 2015
Interest rate, notes payable						5.00%
Notes Payable | Director
Debt Instrument [Line Items]
Note payable balance	25,000
Accrued interest	$ 417
Shares issued on conversion of debt (in shares)	16,608
Pre reverse split shares issued on conversion of debt (in shares)	1,411,720
Pre reverse split share price	$ 0.018
Proceeds from issuance of notes payable		$ 14,074	$ 111,102	$ 4,480	$ 25,000							$ 4,887
Note payable balance	$ 25,000
Accrued interest	$ 417
Shares issued on conversion of debt (in shares)	16,608
Pre reverse split shares issued on conversion of debt (in shares)	1,411,720
Pre reverse split share price	$ 0.018
Gain recorded in additional paid in capital	$ 11,296
Proceeds from issuance of notes payable		$ 14,074	$ 111,102	$ 4,480	$ 25,000							$ 4,887
Interest rate, notes payable		8.00%	8.00%	8.00%	5.00%							8.00%
Interest rate, notes payable		8.00%	8.00%	8.00%	5.00%							8.00%
Series A Notes Payable
Debt Instrument [Line Items]
Note payable balance	50,000
Accrued interest	22,500
Gain on the extinguishment of debt	30,959
Note payable balance	50,000
Accrued interest	22,500
Gain on the extinguishment of debt	$ 30,959
Series A Notes Payable | Common Stock
Debt Instrument [Line Items]
Shares issued on conversion of debt (in shares)	47,370
Pre reverse split shares issued on conversion of debt (in shares)	4,026,484
Pre reverse split share price	$ 0.018
Shares issued on conversion of debt (in shares)	47,370
Pre reverse split shares issued on conversion of debt (in shares)	4,026,484
Pre reverse split share price	$ 0.018
Minimum | Notes Payable | Warrant
Debt Instrument [Line Items]
Expected volatility																173.70%
Risk-free interest rate																1.75%
Expected warrant term																4 years
Expected volatility																173.70%
Risk-free interest rate																1.75%
Expected warrant term																4 years
Maximum | Notes Payable | Warrant
Debt Instrument [Line Items]
Expected volatility																180.70%
Expected warrant term																5 years
Expected volatility																180.70%
Expected warrant term																5 years

Warrant Liability - Additional

Warrant Liability - Additional Information (Detail)	May. 26, 2015USD ($)	Jan. 01, 2015USD ($)$ / sharesshares	Jan. 01, 2014USD ($)$ / sharesshares	Jun. 30, 2015USD ($)Warrant	Dec. 31, 2014USD ($)$ / sharesshares	Jun. 12, 2015USD ($)	Dec. 31, 2012USD ($)
Major Agreements [Line Items]
Warrant liability				$ 3,182,504	$ 6,370,709
Licensing fees payable				2,000,000
Conversion of stock amount				633,333
Fair value of warrants						$ 1,867,417
Convertible Note
Major Agreements [Line Items]
Fair value of warrants						$ 40,000
Series B Convertible Preferred Stock
Major Agreements [Line Items]
Licensing fees payable	$ 6,500,000
Conversion of stock amount				6,500,000
Verify Me | Warrants issued on January 1, 2014
Major Agreements [Line Items]
Fair value of warrant liability				238,447	121,209
Number of warrants issued | shares			6,349,206
Exercise price (in dollars per share) | $ / shares			$ 0.10
Agreements | Verify Me | Research and Development Expense
Major Agreements [Line Items]
Initial fair value of warrant expensed as research and development cost			$ 444,000
Agreements | Zaah Technologies
Major Agreements [Line Items]
Warrant liability							$ 2,400,000
Fair value of warrant liability				$ 1,828,662	$ 787,544
Agreements | Zaah Technologies | Post Reverse Split
Major Agreements [Line Items]
Number of warrants | Warrant				1,094,304
Patent And Technology Agreement
Major Agreements [Line Items]
Exercise price (in dollars per share) | $ / shares		$ 0.10
Additional payment for patent and technology		$ 4,500,000
Discount to market price at time of issuance		10.00%
Current share price (in dollars per share) | $ / shares		$ 0.04
Additional shares issued for patent and technology agreement (in shares) | shares		125,000,000
Number of common stock shares purchased under warrants (in shares) | shares		125,000,000
Patent And Technology Agreement | Stock Options And Warrants
Major Agreements [Line Items]
Number of warrants to be issued(in shares) | shares					250,000,000
Exercise price of warrant to be issued(in dollars per share) | $ / shares					$ 0.02
Warrant to be issued value					$ 4,892,089
Patent And Technology Agreement | Warrant | Stock Options And Warrants
Major Agreements [Line Items]
Dividend yield					0.00%
Expected volatility					229.10%
Risk free interest					1.65%
Expected warrant term					5 years

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Detail)	Jun. 12, 2015USD ($)shares	May. 26, 2015USD ($)$ / sharesshares	Aug. 05, 2013shares	Jan. 31, 2013USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)
Class of Stock [Line Items]
Conversion of preferred stock, shares			12,222,222
Fair value of warrants | $					$ 1,115,395	$ 494,939
Licensing fees | $					$ 2,000,000
Series A- Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock value | $	$ 1,278,501
Preferred stock, shares authorized		441,938
Preferred stock, par value | $ / shares		$ 0.001
Preferred stock convertible ratio		20
Preferred stock, sold	389,668
Preferred stock subscribed by an officer and shareholder	10,667
Unpaid compensation value | $	$ 35,000
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized		1
Preferred stock, par value | $ / shares		$ 0.001
Preferred stock convertible ratio		84,967,321
Licensing fees | $		$ 6,500,000
Pre Reverse Split
Class of Stock [Line Items]
Number of common stock called by warrants (in shares)					4,000,000
Conversion of preferred stock, shares	21,111,111				21,111,111
Pre Reverse Split | Series A- Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		37,564,767
Preferred stock, sold	33,121,777
Preferred stock subscribed by an officer and shareholder	906,736
Pre Reverse Split | Series B Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized		85
Convertible Preferred Stock Subject to Mandatory Redemption [Member]
Class of Stock [Line Items]
Preferred stock value | $				$ 1,000,000
Common Stock
Class of Stock [Line Items]
Number of preferred stock purchased					304,785
Preferred stock converted in to common stock			12,222,222
Conversion of shares of preferred stock to common stock, shares	248,366				248,366
Subscription Agreement
Class of Stock [Line Items]
Convertible preferred stock description					At any time before January 31, 2015, VerifyMe had the right, but not the obligation, to require the Company to repurchase all, but not less than all, of the capital stock of the Company and warrants exercisable for capital stock of the Company held by VerifyMe in exchange for the price originally paid by VerifyMe therefore upon the occurrence of any of the following events:(i) the consummation of any bona fide business acquisition, (ii) the incurrence of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preference on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share.
Excess amount for incurring indebtedness | $					$ 2,000,000
Exercise price of capital stock or warrant | $ / shares					$ 0.03
Fair value of warrants | $				2,995,791
Subscription Agreement | Verify Me
Class of Stock [Line Items]
Beneficial conversion feature at fair market value | $	$ 0					$ 0
Deemed dividend distribution | $				$ 1,000,000
Subscription Agreement | Convertible Preferred Stock | Verify Me
Class of Stock [Line Items]
Number of preferred stock purchased				33,333,333
Subscription Agreement | Common Stock | Verify Me
Class of Stock [Line Items]
Number of common stock called by warrants (in shares)				33,333,333
Value of shares issued | $				$ 1,000,000
Exercise price of warrants | $ / shares				$ 0.12

Fair Value of Financial Instr42

Fair Value of Financial Instruments - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Fair value on a recurring basis	Jun. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability related to fair value of warrants	$ 3,182,504
Total	3,182,504
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability related to fair value of warrants	3,182,504
Total	$ 3,182,504

Fair Value of Financial Instr43

Fair Value of Financial Instruments - Fair Value Measurements within Fair Value Hierarchy of Derivative Liabilities Using Level 3 Inputs (Detail)	6 Months Ended
	Jun. 30, 2015USD ($)
Debt Instrument Fair Value Carrying Value [Abstract]
Beginning balance	$ 6,370,709
Conversion of notes payable, net of interest expense	(33,943)
Conversion of warrants related to licensing fees	(1,867,417)
Change in fair value of derivative liabilities	(1,286,845)
Ending balance	$ 3,182,504

Fair Value of Financial Instr44

Fair Value of Financial Instruments - Additional Information (Detail)	Jun. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]
Assets measured at fair value on recurring basis	$ 0
Assets or liabilities measured at fair value on non-recurring basis	$ 0

Fair Value of Financial Instr45

Fair Value of Financial Instruments - Schedule of Common Stock Purchase Warrants Valuation Assumptions (Detail) - 6 months ended Jun. 30, 2015 - Warrant	Total
Fair Value, Option, Quantitative Disclosures [Line Items]
Annual Dividend Yield	0.00%
Risk-free interest rate	1.01%
Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected Life (Years)	2 years 6 months
Expected volatility	162.00%
Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected Life (Years)	3 years 6 months 4 days
Expected volatility	169.80%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)		Jun. 12, 2015	Jun. 11, 2015	Jan. 01, 2015	Dec. 31, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Stockholders Equity Note [Line Items]
Research and development	[1]					$ 2,016,000	$ 83,887	$ 2,136,386	$ 948,616
Common stock, shares sold		304,785				5,852,646		5,852,646		3,969,106
Common stock, proceeds from sales		$ 50,000						$ 50,000
Number of shares exercised						2,353
Restricted stock units issued			525,000
Restricted stock units, Expense						$ 6,198		$ 6,198
Restricted Stock
Stockholders Equity Note [Line Items]
Stock units outstanding, Fair value			$ 446,250
Share price			$ 0.01
Warrant
Stockholders Equity Note [Line Items]
Shares Issued upon conversion						2,353
Pre Reverse Split
Stockholders Equity Note [Line Items]
Common stock, shares sold		25,906,735
Restricted stock units issued			44,625,000
Patent And Technology Agreement
Stockholders Equity Note [Line Items]
Issuance of shares for services (in shares)				125,000,000
Share price				$ 0.04
Patent And Technology Agreement | Verify Me
Stockholders Equity Note [Line Items]
Worth of common stock to be paid					$ 400,000
Percentage of discount					10.00%
Closing price of share					$ 0.07
Closing price of share after discount					$ 0.063
Research and development					$ 400,000
Patent And Technology Agreement | Pre Reverse Split | Verify Me
Stockholders Equity Note [Line Items]
Issuance of shares for services (in shares)					6,349,206
[1]	includes shares based compensation of $2,000,000 for the three and six months ended June 30, 2015 and $0 and $400,000 for the three and six months ended June 30, 2014, related to licensing agreements.

Stock Options - Additional info

Stock Options - Additional information (Detail)	Jun. 11, 2015USD ($)DirectorEmployee$ / sharesshares	Jun. 30, 2015shares	Dec. 31, 2013shares	Dec. 17, 2003shares	Dec. 31, 2000shares
Stock Option 2003 Plan | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options			20,000,000
Number of options available to be issued			16,600,577
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options available to be issued		484,706
Exercise price, description		The exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). The aggregate fair market value (determined at the time of the grant) of stock for which an employee may exercise Incentive Stock Options under all plans of the company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be Non-Statutory Stock Options, including prices, duration, transferability and limitations on exercise.
Stock options | March 28, 2014 | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued	1,225,000
Exercisable common stock share price | $ / shares	$ 0.85
Number of employees and directors receiving unit grants | Director	2
Expected option life (in years)	5 years
Fair value of option issued expensed immediately | $	$ 993,083
Expected volatility	176.60%
Expected option life (in years)	5 years
Method used to calculate the grant-date fair value of the warrants		Black-Scholes option pricing model
Stock options | March 28, 2014 | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of employees and directors receiving unit grants | Employee	3
Stock options | Pre Reverse Split | March 28, 2014 | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued	104,125,000
Stock options | Minimum | March 28, 2014 | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.74%
Stock options | Maximum | March 28, 2014 | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.75%
Stock options | Stock Option 2000 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options					1,500,000
Stock options | Stock Option 2003 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options				18,000,000
Number of options available to be issued		36,529,988
Number of option issued		1,470,012

Stock Options - Non-Employee St

Stock Options - Non-Employee Stock Option/Warrant Activity (Detail) - Jun. 30, 2015 - Stock Options And Warrants - $ / shares	Total
Option/Warrant Shares
Outstanding, beginning balance	1,425,481
Granted	0
Exercised	(49,412)
Expired	0
Outstanding, ending balance	1,376,069
Exercisable, June 30, 2015	1,376,069
Weighted Average Remaining Life, Exercisable, June 30, 2015 (years)	5 years 2 months 12 days
Weighted Average Exercise Price
Outstanding, beginning balance	$ 8.50
Granted	0
Exercised	0
Expired	0
Outstanding, ending balance	8.66
Exercisable, June 30, 2015	8.66
Minimum
Exercise Price
Outstanding, beginning balance	0.85
Granted	0
Exercised	0.85
Expired	0
Outstanding, ending balance	0.85
Exercisable, June 30, 2015	0.85
Maximum
Exercise Price
Outstanding, beginning balance	12.75
Granted	0
Exercised	8.50
Expired	0
Outstanding, ending balance	12.75
Exercisable, June 30, 2015	$ 12.75

Stock Options - Incentive Stock

Stock Options - Incentive Stock Option Transactions (Detail) - Jun. 30, 2015 - $ / shares	Total
Weighted Average Exercise Price
Outstanding, beginning balance	$ 4.25
Granted	0
Exercised	0
Expired/Returned	0
Outstanding, ending balance	2
Exercisable, June 30, 2015	$ 4.22
Incentive Stock Options [Member]
Option/Warrant Shares
Outstanding, beginning balance	633,725
Granted	1,225,000
Exercised	0
Expired/Returned	(176,471)
Outstanding, ending balance	1,682,255
Exercisable, June 30, 2015	528,824
Weighted Average Remaining Life, Exercisable, June 30, 2015 (years)	8 years 1 month 6 days
Exercised
Granted	$ 0.85
Exercised	0
Minimum | Incentive Stock Options [Member]
Exercised
Outstanding, beginning balance	4.25
Exercised	0
Expired/Returned	4.25
Outstanding, ending balance	4.25
Exercisable, June 30, 2015	4.25
Maximum | Incentive Stock Options [Member]
Exercised
Outstanding, beginning balance	12.75
Exercised	0
Expired/Returned	12.75
Outstanding, ending balance	12.75
Exercisable, June 30, 2015	$ 12.75

Operating Leases - Additional I

Operating Leases - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
General and administrative expense
Operating Leased Assets [Line Items]
Total rent expense under leases	$ 12,642	$ 17,766	$ 32,011	$ 35,493

Operating Leases - Schedule of

Operating Leases - Schedule of Non-cancelable Operating Lease Arrangements for Property (Detail)	Jun. 30, 2015USD ($)
Leases, Operating [Abstract]
2,015	$ 37,926
2,016	31,605
Total	$ 69,531

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	Jun. 12, 2015USD ($)Shareholdershares	Jun. 30, 2015shares	Dec. 31, 2014USD ($)
Schedule of Other Related Party Transactions [Line Items]
Number of shareholders | Shareholder	3
Convertible notes payable | $	$ 317,000		$ 114,000
Amount of accrued interest owed by shareholders | $	$ 42,713
Common Stock
Schedule of Other Related Party Transactions [Line Items]
Common stock shares issued on conversion of debt (in shares)	234,735	755,977
Common Stock | Pre Reverse Split
Schedule of Other Related Party Transactions [Line Items]
Common stock shares issued on conversion of debt (in shares)	19,952,489

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Aug. 10, 2015USD ($)$ / sharesshares	Jul. 09, 2015USD ($)$ / sharesshares	Jun. 30, 2015	Jul. 23, 2015	Jun. 11, 2015USD ($)$ / shares
Subsequent Event [Line Items]
Reverse stock split ratio			85
Restricted Stock
Subsequent Event [Line Items]
Restricted stock units fair value | $					$ 446,250
Closing stock price per share | $ / shares					$ 0.01
Chief Operating Officer | Restricted Stock
Subsequent Event [Line Items]
Vesting period description			Vesting over a three-year period, with one-third vesting the first year and 1/12 vesting ratably on a quarterly basis thereafter.
Subsequent Event
Subsequent Event [Line Items]
Reverse stock split ratio				0.01176
Subsequent Event | Chief Operating Officer
Subsequent Event [Line Items]
Number of options issued		375,000
Exercisable common stock share price | $ / shares		$ 0.85
Stock grant value | $		$ 1,502,219
Dividend yield		0.00%
Expected volatility		180.10%
Risk free interest rate		1.58%
Expected Life (Years)		5 years
Subsequent Event | Chief Operating Officer | Stock options
Subsequent Event [Line Items]
Vesting period		3 years
Subsequent Event | Chief Operating Officer | Restricted Stock
Subsequent Event [Line Items]
Vesting period		3 years
Number of restricted stock issued		225,000
Restricted stock units fair value | $		$ 918,000
Closing stock price per share | $ / shares		$ 4.08
Subsequent Event | Chief Operating Officer | Options Vests Immediately | Restricted Stock
Subsequent Event [Line Items]
Vesting period		1 year
Vesting percentage		33.33%
Subsequent Event | Chief Operating Officer | Option Vests One Year | Restricted Stock
Subsequent Event [Line Items]
Vesting percentage		8.33%
Subsequent Event | Chief Operating Officer | Pre Reverse Split
Subsequent Event [Line Items]
Number of options issued		31,875,000
Exercisable common stock share price | $ / shares		$ 0.01
Subsequent Event | Chief Operating Officer | Pre Reverse Split | Restricted Stock
Subsequent Event [Line Items]
Number of restricted stock issued		19,125,000
Subsequent Event | Chief Financial Officer | Stock options
Subsequent Event [Line Items]
Dividend yield	0.00%
Expected volatility	182.20%
Risk free interest rate	1.62%
Expected Life (Years)	5 years
Options fair value | $	$ 1,107,857
Subsequent Event | Chief Financial Officer | Restricted Stock
Subsequent Event [Line Items]
Restricted stock units fair value | $	$ 727,020
Closing stock price per share | $ / shares	$ 5.77
Subsequent Event | Chief Financial Officer | Options Vests Immediately | Restricted Stock
Subsequent Event [Line Items]
Vesting period	6 months
Number of restricted stock issued	20,000
Subsequent Event | Chief Financial Officer | Option Vests One Year | Restricted Stock
Subsequent Event [Line Items]
Vesting period	3 years
Number of restricted stock issued	100,000
Subsequent Event | Chief Financial Officer | Vesting Over 6 Months | Stock options
Subsequent Event [Line Items]
Number of options issued	200,000
Vesting period	3 years